JAK2 and anemia (phenotype): Ruxolitinib is widely indicated for the treatment of the myeloproliferative neoplasms (MPNs) via inhibition of dysregulated janus kinases (JAK1 and JAK2) despite the side effects such as thrombocytopenia, anemia, and neutropenia [25].